Analysis

Eledon Pharmaceuticals, Inc. (ELDN) Stock Analysis

Eledon Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ELDN.

websiteELDN/analysis/ELDN

Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ELDN.

Stock profile

Ticker

ELDN

Asset type

Stock

Market cap

$302.6M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Eledon Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ELDN primary listing
  • A2QL00
  • 2TK

Latest Eledon Pharmaceuticals, Inc. news

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and I...

Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus...

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at...

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 D...

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated tria...

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney T...

Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ETIRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (...

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug de...

Research sections

Valuation

Review valuation context for Eledon Pharmaceuticals, Inc..

Future growth

Review future growth context for Eledon Pharmaceuticals, Inc..

Past performance

Review past performance context for Eledon Pharmaceuticals, Inc..

Financial health

Review financial health context for Eledon Pharmaceuticals, Inc..

Dividend

Review dividend context for Eledon Pharmaceuticals, Inc..

Management

Review management context for Eledon Pharmaceuticals, Inc..

Ownership

Review ownership context for Eledon Pharmaceuticals, Inc..

Other information

Review other information context for Eledon Pharmaceuticals, Inc..

Community

Review community context for Eledon Pharmaceuticals, Inc..